Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies

被引:106
|
作者
Wu, Q. [1 ]
Bencaz, A. F. [2 ]
Hentz, J. G. [1 ]
Crowell, M. D. [1 ]
机构
[1] Mayo Clin, Coll Med, Scottsdale, AZ 85259 USA
[2] Louisiana State Univ, Sch Med, Hlth Sci Ctr, New Orleans, LA USA
关键词
Antidepressant; Bone fractures; Bone mineral density; Depression; Osteoporosis; Serotonin reuptake inhibitors; HIP-FRACTURES; BONE LOSS; ANTIDEPRESSANTS; PUBLICATION; FALLS; BIAS; MEDICATIONS; PEOPLE; TRENDS; RATES;
D O I
10.1007/s00198-011-1778-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A Studies on use of selective serotonin reuptake inhibitors (SSRIs) and risk of fracture have yielded inconsistent results. This meta-analysis, which pooled results from 13 qualifying cohort and case-control studies, found that SSRIs were associated with a significantly increased risk of fractures. Introduction This study was conducted to assess whether people who take SSRIs are at an increased risk of fracture. Methods We conducted a meta-analysis of observational studies. Relevant studies published by February 2010 were identified through literature searches using MEDLINE (from 1966), EMBASE (from 1988), PsycINFO (from 1806), and manual searching of reference lists. Only cohort or case-control studies that examined the association of SSRIs and risk of fracture and bone loss were included. Data were abstracted independently by two investigators using a standardized protocol; disagreements were resolved by consensus. Random effects models were used for pooled analysis due to heterogeneity in the studies. Results Thirteen studies met inclusion criteria. Overall, SSRI use was associated with a significantly increased risk of fracture (relative risk, RR, 1.72; 95% CI [1.51, 1.95]; P < 0.001). An increased fracture risk associated with SSRIs also was observed in the three studies that adjusted for bone mineral density (RR, 1.70; 95% CI [1.28, 2.25]; P < 0.001) and in the four studies that adjusted for depression (RR 1.74; 95% CI [1.28, 2.36]; P < 0.001). SSRI use was not associated with bone loss in the two cohort studies of women (P = 0.29). The overall association between SSRI use and fracture risk was weaker (RR, 1.40; 95% CI [1.22, 1.61]), though still significant (P < 0.001) in analyses that accounted for apparent publication bias. Conclusions Use of SSRIs is associated with increased risk of fracture. The SSRIs may exert an increased risk of fracture independent of depression and bone mineral density.
引用
收藏
页码:365 / 375
页数:11
相关论文
共 50 条
  • [31] Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies
    Cai, Dawei
    Qin, Jian
    Chen, Guangxia
    Feng, Wan
    Liu, Jun
    MINERVA MEDICA, 2017, 108 (05) : 464 - 472
  • [32] Fish Intake and Ovarian Cancer Risk: A Meta-Analysis of 15 Case-Control and Cohort Studies
    Jiang, Pei-yue
    Jiang, Zhong-bo
    Shen, Ke-xin
    Yue, Ying
    PLOS ONE, 2014, 9 (04):
  • [33] Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies
    de Chambrun, Guillaume Pineton
    Dauchet, Luc
    Gower-Rousseau, Corinne
    Cortot, Antoine
    Colombel, Jean-Frederic
    Peyrin-Biroulet, Laurent
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (08) : 1405 - +
  • [34] Gender of infant and risk of postpartum depression: a meta-analysis based on cohort and case-control studies
    Ye, Ziwei
    Wang, Lesan
    Yang, Tubao
    Chen, Li-Zhang
    Wang, Tingting
    Chen, Letao
    Zhao, Lijuan
    Zhang, Senmao
    Luo, Liu
    Qin, Jiabi
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (13): : 2581 - 2590
  • [35] A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    Papakostas, George I.
    Nelson, J. Craig
    Kasper, Siegfried
    Moeller, Hans-Juergen
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 122 - 127
  • [36] Presence of the Ossific Nucleus and Risk of Osteonecrosis in the Treatment of Developmental Dysplasia of the Hip A Meta-Analysis of Cohort and Case-Control Studies
    Chen, Cynthia
    Doyle, Shevaun
    Green, Daniel
    Blanco, John
    Scher, David
    Sink, Ernest
    Dodwell, Emily R.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2017, 99 (09): : 760 - 767
  • [37] A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
    Zhong, Zhuoyuan
    Wang, Limin
    Wen, Xiaojun
    Liu, Yunyun
    Fan, Yafei
    Liu, Zhonglin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2781 - 2796
  • [38] Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis
    Shin, Doosup
    Oh, Yun Hwan
    Eom, Chun-Sick
    Park, Sang Min
    JOURNAL OF NEUROLOGY, 2014, 261 (04) : 686 - 695
  • [39] Use of selective serotonin reuptake inhibitors and risk of fracture: A systematic review and meta-analysis
    Eom, Chun-Sick
    Lee, Hyun-Ki
    Ye, Sungmin
    Park, Sang Min
    Cho, Kyung-Hwan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (05) : 1186 - 1195
  • [40] Selective Serotonin Reuptake Inhibitors and Gastrointestinal Bleeding: A Meta-Analysis
    Carvajal, A.
    Treceno, C.
    Sainz, M.
    Salado, I.
    Jimeno, N.
    Velasco, V.
    Martin Arias, L.
    DRUG SAFETY, 2011, 34 (10) : 944 - 945